How Novo Nordisk Makes its Money: Revenue Breakdown

Key Takeaways

• Novo Nordisk generated DKK 290.4B (~$42B) in FY2024 revenue — up +25.0% — driven by Ozempic (DKK 140.0B, +41.4%) and Wegovy (DKK 51.0B, +62.9%)
• Revenue comes from selling patent-protected pharmaceutical drugs at premium pricing — Ozempic lists at ~$900/month, Wegovy at ~$1,350/month in the U.S.
• Gross margin: 77.1% — characteristic of major branded pharma; the real cost is R&D/clinical trials (expensed), not manufacturing of the finished drug
• Operating margin: 41.7% — among the highest in all of global pharma, reflecting semaglutide pricing power and the absence of competition for the obesity indication
• Revenue growth is supply-constrained, not demand-constrained — Novo Nordisk cannot manufacture Ozempic and Wegovy fast enough to meet global demand; DKK 40B+ annual capex is being deployed to fix this
• iGaming-style winner-take-most dynamics: Novo Nordisk + Eli Lilly control ~80–85% of the global GLP-1 market — a durable oligopoly built on manufacturing scale and clinical data
• CagriSema Phase 3 disappointment in late 2024 (22.7% weight loss vs. ~25%+ expected) caused a major stock correction; the stock fell from a ~$140 peak to ~$75, resetting valuation
• Patent protection for semaglutide in the U.S. runs to approximately 2032–2033, providing a long runway before biosimilar entry; longer if new formulations extend exclusivity

How Does Novo Nordisk Make its Money?

Novo Nordisk (ticker: NVO on NYSE; NOVO B on Copenhagen Stock Exchange) is a Danish pharmaceutical and biotechnology company and the world’s dominant producer of GLP-1 receptor agonist medicines — a class of drugs that treat type 2 diabetes, obesity, and an expanding list of metabolic conditions. The company earns money the way all branded pharmaceutical companies do: by spending billions of dollars on research and development, winning regulatory approval for drugs that work, and then pricing those drugs at a premium that reflects their clinical value — protected from generic competition by patent law.

Founded in 1923 through the merger of two Danish insulin research institutions, Novo Nordisk spent seven decades building the world’s leading insulin franchise. But the GLP-1 revolution — accelerated by semaglutide’s extraordinary clinical outcomes in diabetes, obesity, and cardiovascular disease — has transformed Novo Nordisk from a large European pharma company into one of the most valuable companies in the world by market capitalization, briefly surpassing $650B before the CagriSema setback in late 2024.

By FY2024, Novo Nordisk’s two GLP-1 drugs (Ozempic and Wegovy) together accounted for 66% of total revenue ($27.8B combined), and the company was so supply-constrained that manufacturing capacity — not physician demand or patient interest — was the primary limit on revenue growth.

Novo Nordisk (NVO) Business Model

The Pharmaceutical Revenue Model: Patents, Pricing, and Proof

Novo Nordisk’s business model rests on four pillars:

1. R&D Investment → Patent Protection → Pricing Power

Drug development is a decades-long, high-risk, high-reward process. Novo Nordisk spent approximately DKK 33B (~$4.8B) on R&D in FY2024 — about 11.3% of revenue. When a drug candidate succeeds in clinical trials and wins regulatory approval, it receives a period of market exclusivity (typically 20 years from patent filing, but effective exclusivity is often 10–12 years from approval). During that window, Novo Nordisk can price the drug based on its clinical value and competitive landscape — not its manufacturing cost. For Ozempic and Wegovy, where manufacturing cost is a small fraction of the list price, the gross margin at the product level is extraordinarily high.

2. Manufacturing Moat: Biologics Are Hard to Make

Semaglutide is a peptide-based biologic — not a small-molecule drug that can be easily synthesized. Manufacturing it requires:

• Fermentation of engineered yeast to produce the active peptide
• Complex purification processes to achieve pharmaceutical purity
• Precise fill/finish processes to load the drug into single-use autoinjector pens
• Cold-chain distribution and quality control

This manufacturing complexity means that even competitors with the intellectual property (e.g., when patents expire) cannot enter the market quickly. Building a biologics manufacturing plant takes 3–5 years and billions of dollars. Novo Nordisk’s 100 years of insulin manufacturing experience and its scale of existing biologics infrastructure is a durable competitive barrier.

3. Clinical Data Credibility: Outcomes That Drive Prescribing

Semaglutide’s clinical profile is extraordinary by pharmaceutical standards:

• Diabetes (SUSTAIN trials): Superior HbA1c reduction vs. competing GLP-1s; approved for cardiovascular risk reduction in T2D patients
• Obesity (STEP trials): Average 15% body weight reduction at 68 weeks on 2.4mg weekly dose (Wegovy)
• Cardiovascular (SELECT trial): 20% reduction in major adverse cardiovascular events (heart attack, stroke, CV death) in obese/overweight adults WITHOUT diabetes — a landmark indication that made Wegovy more than a weight loss drug
• Kidney disease (FLOW trial): Semaglutide demonstrated significant reduction in kidney disease progression in T2D patients — a new approved indication expanding the market

Each new positive clinical outcome expands the eligible patient population and strengthens the prescribing case against competing drugs.

4. Diabetes Heritage and Patient Relationships

Novo Nordisk has been the dominant global supplier of insulin for decades. This means: millions of endocrinologists, primary care physicians, and diabetes patients already have relationships with Novo Nordisk products and sales representatives. When Ozempic launched as a GLP-1 injectable (first approved in 2017), Novo Nordisk could market it through its existing diabetes sales force and leverage its established relationships in diabetes clinics. This distribution advantage accelerated Ozempic’s adoption far faster than a company without that established presence could have achieved.

The GLP-1 Demand Flywheel

Ozempic’s growth was initially driven by diabetes prescribers. But word-of-mouth about its weight loss side effects — via social media, celebrity endorsements, and then mainstream media coverage — created a consumer demand phenomenon unlike almost anything in pharmaceutical history. Demand became self-reinforcing:

1. Social media virality (2022–2023): Celebrities and influencers discussing Ozempic for weight loss drove millions of Americans to ask their doctors about the drug
2. Media coverage: Extensive coverage of the “obesity drug revolution” kept the topic in public consciousness
3. Supply shortage: Paradoxically, the shortage of Wegovy and Ozempic created additional media coverage and consumer urgency
4. SELECT trial results (2023): The cardiovascular outcomes data transformed Wegovy from a “weight loss drug” into a cardiovascular risk management tool — meaning insurance coverage expanded and physician prescribing broadened dramatically
5. Telehealth access: Companies like Hims & Hers and others built prescription access pathways that dramatically lowered the barrier to obtaining GLP-1 prescriptions, further expanding demand

Novo Nordisk (NVO) Competitors

Eli Lilly is Novo Nordisk’s primary GLP-1 competitor and the most significant threat to its market position. Lilly’s tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (obesity) — is a dual GIP/GLP-1 receptor agonist that activates both the GIP and GLP-1 receptors simultaneously. In the SURMOUNT-1 obesity trial, tirzepatide achieved approximately 20–22% average weight loss — comparable to or slightly better than Wegovy. Lilly has also moved aggressively into manufacturing capacity expansion and telehealth distribution partnerships. See the full Eli Lilly vs. Novo Nordisk comparison for a detailed head-to-head.

Amgen is developing MariTide (maridebart cafraglutide) — a GLP-1/GIP bispecific antibody that, unlike semaglutide or tirzepatide (which are weekly or daily injectables), is dosed monthly or potentially quarterly. Early Phase 2 results showed weight loss in the semaglutide-comparable range. If successful, a once-monthly or once-quarterly dosing schedule would be a significant patient convenience advantage.

Pfizer has pursued oral GLP-1 candidates — an important strategic direction since many patients prefer pills to injections. Pfizer’s oral program (danuglipron) experienced setbacks in clinical development due to tolerability issues, demonstrating how difficult oral GLP-1 development is. But large pharma companies with Pfizer’s resources will continue investing in this space.

Hims & Hers Health was a significant compounding threat to Novo Nordisk — during the FDA-declared semaglutide shortage (2022–2025), compounding pharmacies (including Hims & Hers’ telehealth platform) could legally produce and sell compounded semaglutide at significantly lower prices (~$150–$250/month vs. $900+ for branded Ozempic). The FDA’s removal of semaglutide from the shortage list in 2025 effectively ended legal large-scale semaglutide compounding, directly benefiting Novo Nordisk.

Merck and Johnson & Johnson do not currently have competing GLP-1 products but are significant pharma peers competing for R&D talent, manufacturing capacity, distribution infrastructure, and investor capital allocation.

CVS Health and UnitedHealth — as the largest pharmacy benefit managers (PBMs) in the U.S. — are not competitors but are critical intermediaries. They negotiate formulary placement and rebates on Ozempic and Wegovy, determining the net price Novo Nordisk actually receives (significantly below the list price) and influencing patient access. Their coverage decisions have an outsized impact on Wegovy adoption rates.

Revenue Breakdown

All figures in Danish Krone (DKK). Approximate USD conversion at DKK 6.87 per USD. Novo Nordisk’s fiscal year ends December 31.

The FY2024 revenue story is the GLP-1 duopoly in action: Ozempic and Wegovy together account for DKK 191.0B — 66% of total revenue — and grew a combined 48% year-over-year. The insulin segment (+3.9%) represents the stable legacy business that provides predictable cash flows while GLP-1 products drive headline growth. The “Other GLP-1” decline (-6.4%) reflects cannibalization of Victoza (liraglutide, an older weekly GLP-1) and Rybelsus (oral semaglutide at lower doses) by Ozempic — patients and physicians switching to the newer, higher-dose semaglutide product.

Business Segment Deep-Dives

Ozempic (DKK 140.0B, 48% — The Blockbuster)

Ozempic is the single most important drug Novo Nordisk has ever sold and one of the most significant pharmaceutical products in modern medical history. Launched in the U.S. in December 2017 for type 2 diabetes, it is a once-weekly injection of semaglutide (0.5mg, 1mg, or 2mg) delivered via FlexTouch or OzempicPen autoinjector devices.

Why Ozempic generates such extraordinary revenue:

• Diabetes prevalence: Approximately 38M Americans have type 2 diabetes; ~537M worldwide. It is the fastest-growing chronic disease globally.
• Superior efficacy: Ozempic reduces HbA1c (blood sugar) by 1.5–2% and causes average weight loss of 5–10% — both significantly better than most competing oral diabetes drugs (metformin, sulfonylureas, DPP-4 inhibitors)
• Cardiovascular approval: Ozempic is approved to reduce cardiovascular risk in T2D patients with established heart disease — a major commercial driver because cardiologists as well as endocrinologists now prescribe it
• Off-label obesity use: A substantial portion of Ozempic scripts are written for weight loss in non-diabetic patients. The FDA has discouraged this as it diverts supply from diabetic patients, but off-label prescribing remains significant
• U.S. pricing: ~$935 list price per month; after PBM rebates, net price to Novo Nordisk is meaningfully lower, but still extraordinarily profitable

Supply constraint: Ozempic has been on the FDA shortage list, meaning demand exceeded supply. Novo Nordisk’s manufacturing expansion is targeted directly at closing this gap — adding production capacity means revenue can grow without any additional physician or patient demand generation.

Wegovy (DKK 51.0B, 18% — The Obesity Revolution)

Wegovy is the obesity-indication version of semaglutide, approved by the FDA in June 2021 at a dose of 2.4mg weekly. Despite its recent approval, Wegovy is already generating ~$7.4B annually and growing faster than any other product in the portfolio (+62.9% in FY2024).

The SELECT trial was a watershed moment: The results, published in 2023, showed that Wegovy reduced major cardiovascular events (non-fatal MI, non-fatal stroke, or cardiovascular death) by 20% over 5 years in patients who were overweight or obese but did NOT have diabetes. This was the first time any obesity drug had demonstrated cardiovascular risk reduction — transforming Wegovy from a cosmetic/lifestyle drug into a medical necessity for high-risk overweight patients. The cardiovascular indication significantly changes the insurance coverage calculus.

The addressable market is vast: By BMI criteria, approximately 100M+ Americans qualify for Wegovy. By cardiovascular risk criteria (the SELECT population), an estimated 50M+ Americans would be appropriate candidates. Even at low penetration rates, the revenue opportunity is enormous — limited only by supply capacity and insurance access.

Pricing: U.S. list price ~$1,350/month. Novo Nordisk offers a savings card program ($25/month for eligible commercially insured patients), but the full economics accrue when insurance covers the drug at the formulary rate. Medicare coverage for cardiovascular prevention was the policy change that expanded Wegovy access to the largest insured population in the U.S.

Insulin (DKK 53.0B, 18% — The Stable Foundation)

Novo Nordisk’s insulin franchise is the company’s 100-year-old legacy business and still generates $7.7B annually. Key products include:

• Tresiba (insulin degludec): Long-acting basal insulin with an ultra-long duration of action (>42 hours), allowing flexible dosing. Novo Nordisk’s premium insulin product.
• NovoRapid / NovoLog (insulin aspart): Rapid-acting mealtime insulin — the largest volume insulin globally
• Levemir (insulin detemir): Once- or twice-daily long-acting insulin; faces biosimilar competition in some markets
• Awiqli (insulin icodec): Once-weekly basal insulin — a significant innovation that converts the daily injection routine for T2D and T1D patients to a weekly shot (matching Ozempic’s dosing convenience). Approved in Europe and Canada; U.S. approval anticipated

The insulin portfolio grows slowly (+3.9%) but is highly cash-generative and provides the clinical infrastructure and physician relationships that underpin Novo Nordisk’s broader metabolic disease presence.

Other GLP-1: Victoza and Rybelsus (DKK 22.0B, 8% — Declining Legacy)

• Victoza (liraglutide, daily injection): The GLP-1 predecessor to Ozempic — a once-daily rather than once-weekly injection. Now being displaced by Ozempic in most markets. Revenue declining as physicians switch patients to semaglutide.
• Rybelsus (oral semaglutide, 7mg/14mg): The oral tablet formulation of semaglutide. Revenue slightly declining as Ozempic (injectable) dominates the market; higher-dose oral semaglutide in development may re-energize this category.

Rare Disease (DKK 12.5B, 4% — Stable Niche)

Hemophilia treatments (NovoSeven, Esperoct, Alhemo) and growth hormone therapies (Norditropin). A profitable, stable business with lower growth than the diabetes/obesity segments. Not a strategic growth priority given the GLP-1 opportunity size.

Novo Nordisk (NVO) Income Statement

All values in Danish Krone (DKK). Financial data sourced from Novo Nordisk SEC Filings.

Reading the FY2024 income statement: Revenue grew +25% but operating income grew only +22.6% — meaning operating margin compressed slightly (-80 bps) as Novo Nordisk invested aggressively in sales force expansion, manufacturing ramp, and R&D for the next generation of molecules. The net margin compression (-470 bps, from 36.0% to 31.3%) is larger than the operating margin compression, reflecting higher tax rates and currency effects in FY2024. Gross margin compression of -70 bps reflects higher manufacturing costs as new capacity ramps (early-stage facilities have higher per-unit costs before they achieve full operational efficiency). The fundamental gross margin profile of the business (77%+) remains intact.

Novo Nordisk (NVO) Key Financial Metrics

Key Metric Observations

The slight gross margin compression (-70 bps to 77.1%) is not a concern — it reflects the cost of rapid manufacturing scale-up, where new plants operate at sub-optimal utilization rates in early years before production volume justifies the fixed cost base. As new fill/finish capacity reaches full utilization over the next 2–3 years, gross margins should stabilize and potentially expand.

Operating margin at 41.7% is extraordinary by any measure. For context: most consumer goods companies operate at 10–20% operating margins; software companies at 20–30%; even highly profitable pharmaceutical companies like Merck and Pfizer typically operate at 25–35% when not in a peak-cycle drug year. Novo Nordisk’s 41.7% reflects that it is effectively a monopoly for several of its drug categories — there is no therapeutic substitute for a Wegovy patient who is losing 15%+ of body weight with cardiovascular risk reduction.

Net income growing only +8.7% on +25% revenue growth reflects the investment cycle, not a business deterioration. The company is deliberately accepting lower short-term profitability (through R&D, capex, and commercial investment) to maximize the long-term value of the GLP-1 franchise. Return on equity and return on invested capital remain among the highest in global pharma.

Is Novo Nordisk (NVO) Profitable?

Extremely. Novo Nordisk reported DKK 91.0B (~$13.2B) in net income in FY2024 on DKK 290.4B in revenue — a 31.3% net margin. By comparison:

• Eli Lilly — comparable GLP-1 rival, net income ~$10B in FY2024
• Pfizer — net income near zero in FY2024 due to COVID product revenue collapse and write-downs
• Johnson & Johnson — net income ~$14B in FY2024 on ~$90B revenue (~15% net margin)

Novo Nordisk generates massive free cash flow — though the DKK 40B+ annual capex investment means reported FCF is somewhat lower than operating cash flow would suggest. The company returns capital to shareholders through:

• Dividends: Consistent dividend payments growing with earnings
• Share buybacks: Multi-billion DKK annual buyback programs

The profitability position is secure for at least the semaglutide patent protection period (U.S.: approximately 2032–2033), as no approved biosimilar or generic equivalent can enter the market before then.

Where Does Novo Nordisk Spend its Money?

Research & Development (~DKK 33B, ~11% of Revenue)

The most strategically important cost. R&D funds the clinical trials for new indications (FLOW for kidney disease, CVOT extensions), next-generation molecules (CagriSema, amycretin, oral semaglutide at higher doses), and the preclinical pipeline. Every approved new indication for semaglutide extends its commercial lifetime and justifies its price to insurers. Every next-generation molecule that succeeds reduces the patent cliff risk when semaglutide exclusivity eventually expires.

Manufacturing / Capital Expenditure (~DKK 40B+, ~14% of Revenue)

Fill/finish capacity at Chartres (France), Kalundborg (Denmark), and new North Carolina and Iowa (U.S.) facilities. API (active pharmaceutical ingredient) production expansion in Denmark. Autoinjector pen device manufacturing. This is the highest-priority spend in the company — every additional batch of semaglutide that can be manufactured is revenue that can be sold, given demand exceeds supply.

Sales, General & Administrative (~DKK 70B, ~24% of Revenue)

Sales force costs (diabetes and obesity specialists, primary care representatives, managed care account teams), direct-to-consumer advertising for Ozempic and Wegovy, medical affairs (medical science liaisons, clinical education), and corporate overhead. The DTC advertising investment in Ozempic has been among the largest in pharmaceutical history — helping drive the social awareness that made semaglutide a household name.

Cost of Goods Sold (~DKK 66.4B, ~23% of Revenue)

Manufacturing costs for drugs sold: raw materials, fermentation/purification labor, fill/finish operations, quality control, device components, logistics, and royalties. At 22.9% of revenue, this is low relative to most industries — reflecting the high-value, low-physical-cost nature of a patented biologic where the value is in the molecule, not the manufacturing.

Novo Nordisk vs. Comparable Pharmaceutical Companies

Eli Lilly vs. Novo Nordisk comparison: see Eli Lilly vs. Novo Nordisk for full detail.

Novo Nordisk History and Milestones

Novo Nordisk (NVO): What to Watch

1. CagriSema Repositioning and REDEFINE Program The CagriSema Phase 3 disappointment (22.7% weight loss vs. ~25%+ expected) caused the largest single-day market cap decline in Danish history. However, 22.7% weight loss is still greater than Wegovy alone — so CagriSema remains a commercially viable drug, just not the step-change the market had priced in. Watch for: FDA submission timeline, label negotiations, pricing strategy vs. Wegovy, and whether Novo Nordisk pursues additional REDEFINE trials in specific populations where the drug may show greater differentiation.

2. Manufacturing Capacity: Fill/Finish as the Binding Constraint Every DKK invested in manufacturing capacity directly translates to revenue potential. Novo Nordisk’s North Carolina and Denmark facility expansions are the most important capital allocation decisions the company is making. Watch quarterly manufacturing output disclosures, supply to pharmacy commentary, and any announcements of additional site builds or acquisitions of manufacturing partners. The company that can produce more semaglutide wins more revenue — it’s that simple in a supply-constrained market.

3. Eli Lilly Competition: Tirzepatide vs. Semaglutide The GLP-1 market is likely large enough for both Novo Nordisk and Eli Lilly to grow substantially for years. But market share matters for pricing power, commercial relationships, and investor sentiment. Watch head-to-head comparison studies (SURMOUNT-5 directly compared Wegovy and Zepbound), formulary placement decisions by major PBMs (CVS Health, UnitedHealth OptumRx, Express Scripts), and Lilly’s next-generation oral tirzepatide program.

4. Oral Semaglutide Next Generation Rybelsus (current oral semaglutide) at 7mg/14mg doses shows meaningful but lower weight loss than the Wegovy injectable dose. Novo Nordisk is developing higher-dose oral semaglutide (25mg/50mg) that preliminary data suggests could achieve weight loss closer to the injectable. An oral GLP-1 that is as effective as an injectable would enormously expand the addressable market — many patients are willing to take a pill but unwilling to inject. This program is the most important “adjacent” opportunity to watch.

5. Medicare and Insurance Coverage Expansion Wegovy coverage under Medicare Part D has been politically complex — the Inflation Reduction Act authorized coverage for cardiovascular prevention (SELECT indication) but broader obesity coverage requires legislative action. Each policy expansion (major insurer adding Wegovy, state Medicaid programs, employer health plan decisions) translates directly into addressable patients and revenue. Monitor CMS guidance, congressional activity, and major employer benefit disclosures.

6. Patent Cliffs and Biosimilar Timeline U.S. semaglutide patent protection extends to approximately 2032–2033. However, formulation patents, device patents, and method-of-treatment patents can extend effective exclusivity for years beyond the base compound patent. The biosimilar entry timeline will determine the magnitude and timing of eventual Ozempic/Wegovy revenue erosion. Novo Nordisk’s strategy to defend the franchise: launch next-generation molecules (CagriSema, amycretin) well before biosimilar entry to migrate patients to new patents.

7. Amycretin and the Next Generation Pipeline Amycretin is Novo Nordisk’s next-generation molecule — a “unimolecular” dual agonist of both GLP-1 and amylin receptors (contrasting with CagriSema, which is a co-formulation of two separate molecules). Early Phase 2 data showed amycretin achieving weight loss that exceeded either component alone — potentially 20–25%+ in both injectable and oral forms. If amycretin achieves those outcomes in Phase 3 and gets approved, it could become the next Ozempic — a category-defining product that grows Novo Nordisk’s revenue for another decade.

8. GLP-1 Expansion to New Indications: NASH, Sleep Apnea, Addiction Semaglutide’s mechanism appears to have broad metabolic benefits beyond diabetes and obesity. Clinical data suggests potential benefits in: non-alcoholic steatohepatitis (NASH/MASH — fatty liver disease), obstructive sleep apnea (an FDA-approved sleep apnea indication was received in 2024), alcohol use disorder, and Alzheimer’s disease (in early trials). Each approved new indication expands the label and can justify new prescribing and new insurance coverage. The sleep apnea approval specifically opened a new prescribing channel with sleep medicine specialists.

Novo Nordisk (NVO) Financial Summary

Novo Nordisk (NVO) is the world’s leading pharmaceutical and biotechnology company for diabetes and obesity treatment, generating DKK 290.4B (~$42B) in FY2024 revenue — up +25.0% year-over-year. Ozempic (DKK 140.0B, +41.4%) and Wegovy (DKK 51.0B, +62.9%) together account for 66% of total revenue, with both drugs limited by manufacturing supply rather than market demand. Gross margin of 77.1% and operating margin of 41.7% are among the highest in global pharma, reflecting semaglutide’s pricing power and patent protection.

Net income of DKK 91.0B (~$13.2B) funds both an aggressive capex program (DKK 40B+ to expand manufacturing) and substantial capital returns to shareholders. The company has guided for continued revenue growth as manufacturing capacity expands, though the CagriSema Phase 3 setback reset near-term expectations for next-generation molecule contributions.

The long-term thesis: Novo Nordisk and Eli Lilly are building the global infrastructure for treating the obesity epidemic — a condition affecting 1.9 billion adults worldwide and contributing to diabetes, cardiovascular disease, and cancer. Novo Nordisk’s 100-year manufacturing heritage, semaglutide clinical data breadth, and next-generation pipeline position it as the definitive long-term compounder in the most important new drug category of the 21st century.

Related companies include Eli Lilly, Pfizer, Merck, Johnson & Johnson, Amgen, Hims & Hers, CVS Health, and UnitedHealth.

Frequently Asked Questions

How does Novo Nordisk make money? By selling patent-protected pharmaceutical drugs at premium prices — primarily Ozempic (~$900/month, type 2 diabetes) and Wegovy (~$1,350/month, obesity). FY2024: DKK 290.4B (~$42B) total revenue, +25.0% YoY. Revenue is GGR-equivalent: list price minus PBM rebates = net price to Novo Nordisk.

Is Novo Nordisk profitable? Extremely. FY2024: DKK 91.0B (~$13.2B) net income, 31.3% net margin, 41.7% operating margin — among the highest in global pharma. Generates massive free cash flow used for dividends, buybacks, and manufacturing capex.

What is Novo Nordisk’s gross margin? 77.1% in FY2024 (-70 bps YoY). High because patented biologics have enormous pricing power relative to their manufacturing cost. Slight compression reflects manufacturing ramp costs. Long-run gross margins should remain above 75%.

What are Ozempic and Wegovy? Both contain semaglutide — a GLP-1 receptor agonist. Ozempic (lower dose, diabetes approved, 48% of revenue) and Wegovy (higher dose 2.4mg, obesity approved, 18% of revenue). Together: 66% of Novo Nordisk’s FY2024 revenue.

Who are Novo Nordisk’s main competitors? Eli Lilly (Mounjaro/Zepbound = tirzepatide) is the primary GLP-1 rival. Amgen (MariTide in Phase 3), Pfizer (oral GLP-1 program), and AstraZeneca (pipeline) are developing competing drugs. See Eli Lilly vs. Novo Nordisk.

What happened to Novo Nordisk’s stock in 2024? The stock fell from a peak of ~$140 to ~$75 after Phase 3 results for CagriSema (a next-generation weight loss drug) showed ~22.7% average weight loss — better than Wegovy alone but below the ~25%+ the market had expected based on earlier signals.

When do Novo Nordisk’s patents expire? U.S. semaglutide patent protection extends to approximately 2032–2033. Formulation and device patents may extend effective exclusivity further. Novo Nordisk’s strategy to maintain revenue through and beyond the patent cliff: launch next-generation molecules (amycretin, CagriSema) before biosimilar entry.

What is the GLP-1 market opportunity? The global GLP-1 market was ~$50–60B in 2024 and is projected to grow to $150–200B by 2030 as obesity becomes a mainstream treated condition. Novo Nordisk and Eli Lilly hold ~80–85% of this market. The addressable population — obese adults with or without diabetes — is approximately 1 billion people globally.